Funding for this research was provided by:
mittelman integrative oncology family fund
Received: 5 July 2021
Accepted: 17 September 2021
First Online: 26 September 2021
: Study oversight and ethics approval was provided by the Dana-Farber/Harvard Cancer Center Office for Human Research Studies (18-049). All study participants provided written consent to participate in the trial.
: Not applicable.
: RK has received personal fees (consulting) from Strategy Inc, Spark Healthcare, and System Analytic; and serves on the scientific advisory board of Wellium.